Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Anthoney, A"'
Autor:
John P. Neoptolemos, Christopher Halloran, Daniel H. Palmer, Ross Carter, Thilo Hackert, Andrew Scarfe, Bengt Glimelius, Richard Charnley, Eithne Costello, Juan W. Valle, Markus M. Lerch, Markus W. Büchler, Niall C. Tebbutt, Richard J. Jackson, Nils O. Elander, Karen Aughton, Julia Mayerle, William Greenhalf, Anthony Evans, David Cunningham, Fiona Campbell, Alan Anthoney, John R. Mackey, Jennifer Shannon, Paula Ghaneh, David Goldstein
Publikováno v:
Cancers
Volume 13
Issue 22
CANCERS
Cancers, Vol 13, Iss 5758, p 5758 (2021)
Volume 13
Issue 22
CANCERS
Cancers, Vol 13, Iss 5758, p 5758 (2021)
Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer. Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. Cytidine deaminase (CDA), inside or outside of the
Autor:
Lamarca, Angela, Palmer, Daniel H, Wasan, Harpreet Singh, Ross, Paul J, Ma, Yuk Ting, Arora, Arvind, Falk, Stephen, Gillmore, Roopinder, Wadsley, Jonathan, Patel, Kinnari, Anthoney, Alan, Maraveyas, Anthony, Iveson, Tim, Waters, Justin S, Hobbs, Claire, Barber, Safia, Ryder, W David, Ramage, John, Davies, Linda M, Bridgewater, John A, Valle, Juan W, Grp, Adv Biliary Canc Working
Publikováno v:
Lamarca, A, Palmer, D H, Wasan, H S, Ross, P J, Ma, Y T, Arora, A, Falk, S, Gillmore, R, Wadsley, J, Patel, K, Anthoney, A, Maraveyas, A, Iveson, T, Waters, J S, Hobbs, C, Barber, S, Ryder, W D, Ramage, J, Davies, L M, Bridgewater, J A & Valle, J W 2021, ' Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial ', The Lancet Oncology, vol. 22, no. 5, pp. 690-701 . https://doi.org/10.1016/S1470-2045(21)00027-9
LANCET ONCOLOGY
The Lancet. Oncology
LANCET ONCOLOGY
The Lancet. Oncology
Background\ud \ud Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b648e2fdd5880868d388d1b0aac4b6ac
https://linkinghub.elsevier.com/retrieve/pii/S1470204521000279
https://linkinghub.elsevier.com/retrieve/pii/S1470204521000279
Autor:
Richard J. Ellis, Harpreet Wasan, Karen McAdam, S. Arif, Lisa Bax, Roopinder Gillmore, Jonathan Wadsley, Duncan I. Jodrell, Sebastian Cummins, Albrecht Neesse, Pippa Corrie, Yuk Ting Ma, Daniel H. Palmer, Rebecca Brais, J. Evans, David Propper, Aarthi Gopinathan, A. Chhabra, Martin Scott-Brown, R. Skells, Andrea Machin, K. Dalchau, A. Dayim, P. Bundi, Christopher Isherwood, Bristi Basu, C. Lwuji, John Bridgewater, David A. Tuveson, Alan Anthoney, Lucy Wall, S Falk, Juan W. Valle, Wendi Qian
Publikováno v:
British Journal of Cancer
Corrie, P G, Qian, W, Basu, B, Valle, J, Falk, S, Iwuji, C, Wasan, H, Palmer, D, Scott-Brown, M, Wadsley, J, Arif, S, Bridgewater, J, Propper, D, Gillmore, R, Gopinathan, A, Skells, R, Bundi, P, Brais, R, Dalchau, K, Bax, L, Chhabra, A, Machin, A, Dayim, A, McAdam, K, Cummins, S, Wall, L, Ellis, R, Anthoney, A, Evans, J, Ma, Y T, Isherwood, C, Neesse, A, Tuveson, D & Jodrell, D I 2020, ' Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma ', BJC, vol. 122, pp. 1760–1768 . https://doi.org/10.1038/s41416-020-0846-2
Corrie, P G, Qian, W, Basu, B, Valle, J, Falk, S, Iwuji, C, Wasan, H, Palmer, D, Scott-Brown, M, Wadsley, J, Arif, S, Bridgewater, J, Propper, D, Gillmore, R, Gopinathan, A, Skells, R, Bundi, P, Brais, R, Dalchau, K, Bax, L, Chhabra, A, Machin, A, Dayim, A, McAdam, K, Cummins, S, Wall, L, Ellis, R, Anthoney, A, Evans, J, Ma, Y T, Isherwood, C, Neesse, A, Tuveson, D & Jodrell, D I 2020, ' Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma ', BJC, vol. 122, pp. 1760–1768 . https://doi.org/10.1038/s41416-020-0846-2
Background Nab-paclitaxel plus gemcitabine (nabP+gemcitabine) offers modest survival gains for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Sequential scheduling of nabP+gemcitabine in a PDAC mouse model improved efficacy; this h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9399cbe124eda4393bc1c1e2297d6732
Autor:
Sofia Stamatopoulou, Magdy Nasralla, Vikki Owen-Holt, George Papaxoinis, Alan Anthoney, Theodora Germetaki, Zoe Kordatou, Wasat Mansoor, Jamie M J Weaver, Konstantinos Kamposioras
Publikováno v:
Journal of Gastrointestinal Surgery. 23:1729-1741
The aim of this cohort study was to assess the benefit that patients with lower esophageal or gastroesophageal junction (E/GEJ) adenocarcinoma receive by continuing perioperative chemotherapy post-surgery. Three hundred twelve patients underwent radi
Autor:
John Bridgewater, Stephen Falk, Kinnari Patel, Alan Anthoney, Harpreet Wasan, W David J Ryder, Safia Barber, Juan W. Valle, Daniel H. Palmer, Yuk Ting Ma, Roopinder Gillmore, Arvind Arora, Jonathan Wadsley, John Ramage, Angela Lamarca, Claire Hobbs, Timothy Iveson, Justin S. Waters, Linda Davies, Paul Ross, Anthony Maraveyas
Publikováno v:
The Lancet Oncology. 22:e288-e289
Autor:
Mark R. Middleton, P S Virdee, Leena Elhussein, Martin Eatock, M Goff, Sharon Love, Anne Thomas, Stephen Falk, Joanna Moschandreas, Richard C. Turkington, D. Alan Anthoney, L Collins, Simon Lord
Publikováno v:
Thomas, A, Virdee, P S, Eatock, M, Lord, S R, Falk, S, Anthoney, D A, Turkington, R C, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J & Middleton, M R 2020, ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ', European Journal of Cancer, vol. 124, pp. 131-141 . https://doi.org/10.1016/j.ejca.2019.10.010
European Journal of Cancer
European Journal of Cancer
Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3f4d7b04b1b1073ec0ebfa84b2946
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
Autor:
Angela Lamarca, Daniel Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting Ma, Arvid Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Tim Iveson, Justin Waters, Claire Hobbs, Safia Barber, David Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle, Advanced Biliary Cancer (ABC) Worki Group
Publikováno v:
SSRN Electronic Journal.
Background: Advanced biliary tract cancer (ABC) has a poor prognosis for which cisplatin-gemcitabine is the reference first-line chemotherapy. No robust evidence is available for second-line chemotherapy. Methods: Patients with ABC who progressed on
Autor:
Alan Anthoney, Daniel Otter
Publikováno v:
Endocrine Abstracts.
Autor:
Jones, Robert P, Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M, Palmer, Daniel H, Campbell, Fiona, Valle, Juan W, Faluyi, Olusola, O'Reilly, Derek A, Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R, Middleton, Gary William, Cummins, Sebastian, Ross, Paul J, Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M, Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W, Neoptolemos, John P, Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, Canc, European Study Grp Pancreatic
Publikováno v:
JAMA SURGERY
Importance The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2629aca696c2918ceb890417c1c70357
Autor:
Duncan I. Jodrell, Daniel H. Palmer, Sarah Halford, J. Evans, Lisa V. Hampson, Balaji Venugopal, Robert McLeod, Mirela Hategan, Natalie Cook, Helen Turner, Donna Michelle Smith, Bristi Basu, Aarthi Gopinathan, Michael Nebozhyn, D. Alan Anthoney, David A. Tuveson, William P. Steward, David Propper, Hayley Farmer-Hall
Publikováno v:
Cook, N, Basu, B, Smith, D M, Gopinathan, A, Evans, J, Steward, W P, Palmer, D, Propper, D, Venugopal, B, Hategan, M, Anthoney, D A, Hampson, L V, Nebozhyn, M, Tuveson, D, Farmer-Hall, H, Turner, H, McLeod, R, Halford, S & Jodrell, D 2018, ' A phase i trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma ', British Journal of Cancer, vol. 118, no. 6, pp. 793-801 . https://doi.org/10.1038/bjc.2017.495
British Journal of Cancer
British Journal of Cancer
Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by g-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine. Methods: A multi-centre, non-ra